KR20040018354A - 범용 다수-변이체 검출 시스템 - Google Patents
범용 다수-변이체 검출 시스템 Download PDFInfo
- Publication number
- KR20040018354A KR20040018354A KR10-2003-7013577A KR20037013577A KR20040018354A KR 20040018354 A KR20040018354 A KR 20040018354A KR 20037013577 A KR20037013577 A KR 20037013577A KR 20040018354 A KR20040018354 A KR 20040018354A
- Authority
- KR
- South Korea
- Prior art keywords
- nucleic acid
- reverse primer
- sequence
- forward primer
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000001514 detection method Methods 0.000 title abstract description 56
- 239000000523 sample Substances 0.000 claims abstract description 142
- 238000000034 method Methods 0.000 claims abstract description 67
- 230000003321 amplification Effects 0.000 claims description 116
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 116
- 230000002441 reversible effect Effects 0.000 claims description 112
- 150000007523 nucleic acids Chemical class 0.000 claims description 107
- 125000003729 nucleotide group Chemical group 0.000 claims description 104
- 239000002773 nucleotide Substances 0.000 claims description 101
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 77
- 108020004707 nucleic acids Proteins 0.000 claims description 75
- 102000039446 nucleic acids Human genes 0.000 claims description 75
- 238000003752 polymerase chain reaction Methods 0.000 claims description 72
- 230000000295 complement effect Effects 0.000 claims description 53
- 238000006243 chemical reaction Methods 0.000 claims description 47
- 239000012634 fragment Substances 0.000 claims description 46
- 241000711549 Hepacivirus C Species 0.000 claims description 39
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 26
- 238000009396 hybridization Methods 0.000 claims description 26
- 241000700605 Viruses Species 0.000 claims description 25
- 230000002452 interceptive effect Effects 0.000 claims description 20
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- -1 antroquinone Chemical compound 0.000 claims description 6
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000975 dye Substances 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 claims description 4
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 4
- 239000001018 xanthene dye Substances 0.000 claims description 4
- 230000000051 modifying effect Effects 0.000 claims description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 3
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 3
- CZWUESRDTYLNDE-UHFFFAOYSA-N (2z)-2-[(2e,4e,6e)-7-[1-(5-carboxypentyl)-3,3-dimethyl-5-sulfoindol-1-ium-2-yl]hepta-2,4,6-trienylidene]-1-ethyl-3,3-dimethylindole-5-sulfonate Chemical compound CC1(C)C2=CC(S([O-])(=O)=O)=CC=C2N(CC)\C1=C/C=C/C=C/C=C/C1=[N+](CCCCCC(O)=O)C2=CC=C(S(O)(=O)=O)C=C2C1(C)C CZWUESRDTYLNDE-UHFFFAOYSA-N 0.000 claims description 2
- RGNHAWFQWRAADF-UHFFFAOYSA-N 1-[4-[[4-(dimethylamino)phenyl]diazenyl]phenyl]pyrrole-2,5-dione Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(N2C(C=CC2=O)=O)C=C1 RGNHAWFQWRAADF-UHFFFAOYSA-N 0.000 claims description 2
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 claims description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 claims description 2
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims description 2
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- RDXLYGJSWZYTFJ-UHFFFAOYSA-N Niridazole Chemical compound S1C([N+](=O)[O-])=CN=C1N1C(=O)NCC1 RDXLYGJSWZYTFJ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 claims description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 claims description 2
- 229940011411 erythrosine Drugs 0.000 claims description 2
- 235000012732 erythrosine Nutrition 0.000 claims description 2
- 239000004174 erythrosine Substances 0.000 claims description 2
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 claims description 2
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 claims description 2
- 229940107698 malachite green Drugs 0.000 claims description 2
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229960005130 niridazole Drugs 0.000 claims description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 238000010223 real-time analysis Methods 0.000 claims 1
- 244000052769 pathogen Species 0.000 abstract description 12
- 230000001717 pathogenic effect Effects 0.000 abstract description 5
- 241000702617 Human parvovirus B19 Species 0.000 abstract description 2
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 239000000047 product Substances 0.000 description 92
- 238000003757 reverse transcription PCR Methods 0.000 description 31
- 238000003556 assay Methods 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 210000002381 plasma Anatomy 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 208000030507 AIDS Diseases 0.000 description 9
- 238000000137 annealing Methods 0.000 description 9
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 7
- 238000010804 cDNA synthesis Methods 0.000 description 7
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 241000560067 HIV-1 group M Species 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 102000054767 gene variant Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000711553 Hepatitis C virus (isolate H) Species 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000000295 emission spectrum Methods 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 241000560056 HIV-1 group O Species 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 241000831652 Salinivibrio sharmensis Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000006224 matting agent Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- FTBBGQKRYUTLMP-UHFFFAOYSA-N 2-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C1=CC=CN1 FTBBGQKRYUTLMP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- VTRBOZNMGVDGHY-UHFFFAOYSA-N 6-(4-methylanilino)naphthalene-2-sulfonic acid Chemical compound C1=CC(C)=CC=C1NC1=CC=C(C=C(C=C2)S(O)(=O)=O)C2=C1 VTRBOZNMGVDGHY-UHFFFAOYSA-N 0.000 description 1
- UKLNSYRWDXRTER-UHFFFAOYSA-N 7-isocyanato-3-phenylchromen-2-one Chemical compound O=C1OC2=CC(N=C=O)=CC=C2C=C1C1=CC=CC=C1 UKLNSYRWDXRTER-UHFFFAOYSA-N 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
- NLSUMBWPPJUVST-UHFFFAOYSA-N 9-isothiocyanatoacridine Chemical compound C1=CC=C2C(N=C=S)=C(C=CC=C3)C3=NC2=C1 NLSUMBWPPJUVST-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- ZFHJMXRCWJRWLU-UHFFFAOYSA-N O1N=NC2=C1C=CC=C2.O2C(=NC1=C2C=CC=C1)C1=CC=C(C=C1)N1C(C=CC1=O)=O Chemical class O1N=NC2=C1C=CC=C2.O2C(=NC1=C2C=CC=C1)C1=CC=C(C=C1)N1C(C=CC1=O)=O ZFHJMXRCWJRWLU-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 150000005002 naphthylamines Chemical class 0.000 description 1
- 125000005184 naphthylamino group Chemical group C1(=CC=CC2=CC=CC=C12)N* 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003220 pyrenes Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
- Small-Scale Networks (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28433401P | 2001-04-17 | 2001-04-17 | |
| US60/284,334 | 2001-04-17 | ||
| PCT/US2002/012035 WO2002083927A2 (en) | 2001-04-17 | 2002-04-17 | Universal multi-variant detection system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20040018354A true KR20040018354A (ko) | 2004-03-03 |
Family
ID=23089805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2003-7013577A Abandoned KR20040018354A (ko) | 2001-04-17 | 2002-04-17 | 범용 다수-변이체 검출 시스템 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US7348164B2 (https=) |
| EP (1) | EP1390544B1 (https=) |
| JP (1) | JP4271944B2 (https=) |
| KR (1) | KR20040018354A (https=) |
| CN (1) | CN1279182C (https=) |
| AT (1) | ATE346958T1 (https=) |
| AU (1) | AU2002307359B2 (https=) |
| CA (1) | CA2444174A1 (https=) |
| DE (1) | DE60216445T2 (https=) |
| ES (1) | ES2278043T3 (https=) |
| WO (1) | WO2002083927A2 (https=) |
| ZA (1) | ZA200308906B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2444174A1 (en) * | 2001-04-17 | 2002-10-24 | The New York Blood Center, Inc. | Universal multi-variant detection system |
| EP2251441B1 (en) * | 2004-02-10 | 2013-05-08 | F. Hoffmann-La Roche AG | Detection of parvovirus B19 |
| AU2011253599B2 (en) * | 2004-09-30 | 2013-12-12 | Gen-Probe Incorporated | Assay for detecting and quantifying HIV-1 |
| DK2975139T3 (da) * | 2004-09-30 | 2019-12-09 | Gen Probe Inc | Assay til at detektere og kvantificere hiv-1 |
| US7833716B2 (en) | 2006-06-06 | 2010-11-16 | Gen-Probe Incorporated | Tagged oligonucleotides and their use in nucleic acid amplification methods |
| EP3095873B1 (en) | 2006-12-21 | 2018-04-18 | Gen-Probe Incorporated | Methods and compositions for nucleic acid amplification |
| WO2010105275A2 (en) | 2009-03-13 | 2010-09-16 | Cornell University | Method to assess human allograft status from microrna expression levels |
| US8512955B2 (en) | 2009-07-01 | 2013-08-20 | Gen-Probe Incorporated | Methods and compositions for nucleic acid amplification |
| US9746479B2 (en) | 2010-03-09 | 2017-08-29 | Cornell University | Methods and compositions to predict and detect acute rejection |
| US9932628B2 (en) | 2012-07-27 | 2018-04-03 | Gen-Probe Incorporated | Dual reference calibration method and system for quantifying polynucleotides |
| KR101377824B1 (ko) * | 2012-11-19 | 2014-04-01 | 가톨릭대학교 산학협력단 | 수인성 바이러스 검출용 프라이머 및 이를 포함하는 검출 키트 |
| CN103901000B (zh) * | 2012-12-26 | 2016-09-28 | 江南大学 | 一种基于荧光共振能量转移检测伏马菌毒素b1的方法 |
| US9758828B2 (en) | 2013-01-31 | 2017-09-12 | Cornell University | Methods to detect, treat and prevent acute cellular rejection in kidney allografts |
| US9982301B2 (en) | 2014-01-07 | 2018-05-29 | Cornell University | Urine mRNA profile and acute dysfunction of kidney allograft |
| US20170032100A1 (en) | 2014-04-10 | 2017-02-02 | The Trustees Of The University Of Pennslyvania | Use of micro-ribonucleic acid (mirna) to diagnose transplant rejection and tolerance of immunosuppression therapy |
| CA2978696A1 (en) | 2015-02-03 | 2016-08-11 | The Trustees Of The University Of Pennsylvania | Novel methods for early identification of bone healing ability in injured patients |
| WO2017212023A1 (en) * | 2016-06-10 | 2017-12-14 | Roche Diagnostics Gmbh | Compositions and methods for detection of hepatitis c virus genotype 3 |
| CN110699353A (zh) * | 2019-07-26 | 2020-01-17 | 安徽大学 | 一种靶向端粒的核酸探针 |
| CN120265769A (zh) * | 2023-10-08 | 2025-07-04 | 迈克生物股份有限公司 | 引物探针组合物、核酸检测方法及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925517A (en) * | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| US6007983A (en) * | 1995-12-22 | 1999-12-28 | Visible Genetics Inc. | Method and kit for evaluation of HIV mutations |
| AU713667B2 (en) * | 1996-04-12 | 1999-12-09 | Phri Properties, Inc. | Detection probes, kits and assays |
| US6117635A (en) * | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US6037130A (en) * | 1998-07-28 | 2000-03-14 | The Public Health Institute Of The City Of New York, Inc. | Wavelength-shifting probes and primers and their use in assays and kits |
| WO2000068436A1 (en) * | 1999-05-07 | 2000-11-16 | Nationales Zentrum Für Retroviren | Detection system for human immunodeficiency virus based on nucleic acid amplification |
| US6759193B2 (en) | 1999-07-28 | 2004-07-06 | The Government Of The Republic Of Singapore | Detection of human hepatitis B virus surface antigen mutants by specific amplification and its application on gene chip |
| CA2444174A1 (en) * | 2001-04-17 | 2002-10-24 | The New York Blood Center, Inc. | Universal multi-variant detection system |
-
2002
- 2002-04-17 CA CA002444174A patent/CA2444174A1/en not_active Abandoned
- 2002-04-17 US US10/399,843 patent/US7348164B2/en not_active Expired - Lifetime
- 2002-04-17 ES ES02762133T patent/ES2278043T3/es not_active Expired - Lifetime
- 2002-04-17 JP JP2002582264A patent/JP4271944B2/ja not_active Expired - Fee Related
- 2002-04-17 CN CNB028102681A patent/CN1279182C/zh not_active Expired - Fee Related
- 2002-04-17 WO PCT/US2002/012035 patent/WO2002083927A2/en not_active Ceased
- 2002-04-17 DE DE60216445T patent/DE60216445T2/de not_active Expired - Lifetime
- 2002-04-17 AU AU2002307359A patent/AU2002307359B2/en not_active Ceased
- 2002-04-17 EP EP02762133A patent/EP1390544B1/en not_active Expired - Lifetime
- 2002-04-17 AT AT02762133T patent/ATE346958T1/de not_active IP Right Cessation
- 2002-04-17 KR KR10-2003-7013577A patent/KR20040018354A/ko not_active Abandoned
-
2003
- 2003-11-14 ZA ZA200308906A patent/ZA200308906B/en unknown
-
2008
- 2008-01-28 US US12/011,603 patent/US8192939B2/en not_active Expired - Fee Related
-
2012
- 2012-04-26 US US13/457,123 patent/US20120258446A1/en not_active Abandoned
-
2013
- 2013-04-04 US US13/857,069 patent/US20130288231A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130288231A1 (en) | 2013-10-31 |
| JP2004532027A (ja) | 2004-10-21 |
| AU2002307359B2 (en) | 2007-09-13 |
| ATE346958T1 (de) | 2006-12-15 |
| US7348164B2 (en) | 2008-03-25 |
| ES2278043T3 (es) | 2007-08-01 |
| WO2002083927A2 (en) | 2002-10-24 |
| ZA200308906B (en) | 2004-11-23 |
| HK1065825A1 (zh) | 2005-03-04 |
| EP1390544A2 (en) | 2004-02-25 |
| EP1390544A4 (en) | 2004-07-14 |
| DE60216445D1 (de) | 2007-01-11 |
| US20120258446A1 (en) | 2012-10-11 |
| CN1279182C (zh) | 2006-10-11 |
| US20110053138A1 (en) | 2011-03-03 |
| EP1390544B1 (en) | 2006-11-29 |
| JP4271944B2 (ja) | 2009-06-03 |
| WO2002083927A3 (en) | 2003-03-20 |
| US8192939B2 (en) | 2012-06-05 |
| US20040053284A1 (en) | 2004-03-18 |
| CN1509338A (zh) | 2004-06-30 |
| CA2444174A1 (en) | 2002-10-24 |
| DE60216445T2 (de) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8192939B2 (en) | Universal multi-variant detection system | |
| JP5205346B2 (ja) | Ｈｉｖ−１の増幅及び検出試薬 | |
| AU2002307359A1 (en) | Universal multi-variant detection system | |
| US10655190B2 (en) | Compositions and methods for detection of Zika virus | |
| US9080218B2 (en) | HIV type and subtype detection | |
| JP2020092721A (ja) | ターゲット核酸検出のための二重プローブアッセイ | |
| CA2913729C (en) | Real-time pcr point mutation assays for detecting hiv-1 resistance to antiviral drugs | |
| US20250340957A1 (en) | Assays for the Detection of SARS-CoV2 Mutants | |
| KR102653475B1 (ko) | 코로나 바이러스 동시 검출용 조성물 및 검출 방법 | |
| WO2017164741A2 (en) | Detection of zika virus nucleic acid | |
| US20240240273A1 (en) | Compositions and Methods for Detecting Hepatitis Delta Virus by a Dual-Target Assay | |
| JP6956800B2 (ja) | アデノウイルス、メタニューモウイルス、および／またはライノウイルス核酸を検出するための組成物、方法、およびキット | |
| KR102741691B1 (ko) | SARS-CoV-2 변이 선별용 다중 LAMP 조성물 및 이의 용도 | |
| US12421560B2 (en) | Assays for the detection of SARS-CoV-2 mutants | |
| JP2019524123A (ja) | 核酸の増幅及び検出／定量の効率を改良するためのヘルパーオリゴヌクレオチド | |
| AU2016202864B2 (en) | Assay for detecting and quantifying HIV-1 | |
| HK1065825B (en) | Universal multi-variant detection system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20031017 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20070322 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20080430 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20081030 Patent event code: PE09021S02D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20090630 |
|
| NORF | Unpaid initial registration fee | ||
| PC1904 | Unpaid initial registration fee |